Modern Pediatrics. Ukraine. 2021. 2(114): 40-57. doi 10.15574/SP.2021.114.40
Охотнікова О. М.², Ткачева Т. М.¹, Романчук А. А.¹, Грищенко О. М.², Семененко Л. В.^2
1Національний університет охорони здоров'я України імені П.Л. Шупика, м. Київ
²Національна дитяча спеціалізована лікарня «ОХМАТДИТ», м. Київ, Україна

Для цитування: Охотнікова ОМ, Ткачева ТМ, Романчук АА, Грищенко ОМ, Семененко ЛВ. (2021). Сучасні підходи до лікування запальних захворювань кишечника в дітей відповідно до останніх рекомендацій Європейської організації з вивчення хвороби Крона і коліту, Європейського товариства дитячих гастроентерологів, гепатологів та нутриціологів. Сучасна педіатрія. Україна. 2(114): 40-57. doi 10.15574/SP.2021.114.40
Стаття надійшла до редакції 17.11.2020 р., прийнята до друку 09.03.2021 р.

Сучасне амбулаторне ведення виразкового коліту (ВК) залишається складним завданням, оскільки 20% дітей досі потребують проведення колектомії. Тому Європейська організація з вивчення хвороби Крона і коліту (ECCO) та Європейське товариство дитячих гастроентерологів, гепатологів та нутриціологів (ESPGHAN), прагнучи стандартизувати щоденне лікування запального захворювання кишечника (ЗЗК), розробили протокол ведення та лікування дітей, хворих на ВК. На підставі проведеного аналізу медичного наукового пошуку з подальшою доказовою оцінкою кожного положення були оновлені рекомендації 2012 року.
Мета — висвітлити положення оновленого протоколу щодо терапевтичного ведення дітей з ВК та закріпити матеріал на клінічному прикладі.
Матеріали та методи. Викладено оновлені рекомендації ECCO та ESPGHAN (2018) щодо лікування ЗЗК у дітей, алгоритму індукції і підтримки ремісії ВК і ЗЗК не класифікованого. Наведено клінічний випадок для прикладу застосування алгоритму індукції і підтримки ремісії ЗЗК у дітей, оцінки тяжкості, надано схему подальшого ведення пацієнтів з цією патологією.
Результати та висновки. Поновлені рекомендації ECCO та ESPGHAN полегшують проведення лікування ВК і ЗЗК некласифікованих, надають чітку схему спостереження за дітьми з цією патологією, що поліпшує результати лікування та якість життя маленьких пацієнтів.
Дослідження виконано відповідно до принципів Гельсінської Декларації. На проведення досліджень отримано інформовану згоду батьків дитини.
Автори заявляють про відсутність конфлікту інтересів.
Ключові слова: виразковий коліт, рекомендації, діти, анти-ФНП, кальпротектин, некласифіковані запальні захворювання кишечника, моніторинг, індекс активності, лікування.
ЛІТЕРАТУРА

1. Abdelrazeq AS, Kandiyil N, Botterill ID et al. (2008). Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 10: 805-813. https://doi.org/10.1111/j.1463-1318.2007.01413.x; PMid:18005192

2. Alexandre B, Vandermeeren Y, Dewit O et al. (2016). Optic neuritis associated or not with TNF antagonists in patients with inflammatory bowel disease. J Crohns Colitis. 10: 541-548. https://doi.org/10.1093/ecco-jcc/jjw003; PMid:26759360 PMCid:PMC4957451

3. Barabino A, Torrente F, Ventura A et al. (2002). Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther. 16: 1125-1130. https://doi.org/10.1046/j.1365-2036.2002.01269.x; PMid:12030954

4. Baud O, Goulet O, Canioni D et al. (2001). Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med. 344: 1758-1762. https://doi.org/10.1056/NEJM200106073442304; PMid:11396442

5. Beattie RM, Nicholls SW, Domizio P et al. (1996). Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 22: 373-379. https://doi.org/10.1097/00005176-199605000-00006; PMid:8732900

6. Begue B, Verdier J, Rieux Laucat F et al. (2011). Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 106: 1544-1555. https://doi.org/10.1038/ajg.2011.112; PMid:21519361

7. Benchimol EI, Mack DR, Nguyen GC et al. (2014). Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology. 147: 803-813. https://doi.org/10.1053/j.gastro.2014.06.023; PMid:24951840

8. Bigorgne AE, Farin HF, Lemoine R et al. (2013). TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest. 124: 328-337. https://doi.org/10.1172/JCI71471; PMid:24292712 PMCid:PMC3871247

9. Cakir M, Ozgenc F, Yusekkaya HA et al. (2011). Steroid response in moderate to severe pediatric ulcerative colitis: a single center's experience. World J Pediatr. 7: 50-53. https://doi.org/10.1007/s12519-011-0245-0; PMid:21191776

10. Carter MJ, Di Giovine FS, Cox A et al. (2001). The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology. 121: 805-811. https://doi.org/10.1053/gast.2001.28017; PMid:11606494

11. Cohen RD, Dalal SR. (2015). Systematic review: rectal therapies for the treatment of distal forms of ulcerative colitis. Inflamm Bowel Dis. 21: 1719-1736. https://doi.org/10.1097/MIB.0000000000000379; PMid:26020604

12. Connell WR, Kamm MA, Ritchie JK et al. (1993). Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 34: 1081-1085. https://doi.org/10.1136/gut.34.8.1081; PMid:8174958 PMCid:PMC1374358

13. Connolly MP, Poole CD, Currie CJ et al. (2009). Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion. 80: 241-246. https://doi.org/10.1159/000235916; PMid:19828955

14. Damen GM, van Krieken JH, Hoppenreijs E et al. (2010). Overlap, common features, and essential differences in pediatric granulomatous inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 51: 690-697. https://doi.org/10.1097/MPG.0b013e3181dc0d73; PMid:20683205

15. Dharmaraj R, Dasgupta M, Simpson P et al. (2016). Predictors of pouchitis after ileal pouch-anal anastomosis in children. J Pediatr Gastroenterol Nutr. 63: e58-62. https://doi.org/10.1097/MPG.0000000000001279; PMid:27243421

16. Dhillon SS, Fattouh R, Elkadri A et al. (2014). Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology. 147: 680-689. https://doi.org/10.1053/j.gastro.2014.06.005; PMid:24931457

17. Dignass A, Eliakim R, Magro F et al. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 6: 965-990. https://doi.org/10.1016/j.crohns.2012.09.003; PMid:23040452

18. Dotson JL, Hyams JS, Markowitz J et al. (2010). Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 51: 140-145. https://doi.org/10.1097/MPG.0b013e3181ca4db4; PMid:20453677

19. Fabre A, Charroux B, Martinez Vinson C et al. (2012). SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. Am J Hum Genet. 90: 689-692. https://doi.org/10.1016/j.ajhg.2012.02.009; PMid:22444670 PMCid:PMC3322239

20. Fabre A, Martinez Vinson C, Roquelaure B et al. (2011). Novel mutations in TTC37 associated with tricho-hepato-enteric syndrome. Hum Mutat. 32: 277-281. https://doi.org/10.1002/humu.21420; PMid:21120949

21. Feagan BG, Chande N, MacDonald JK. (2013). Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews. Inflamm Bowel Dis. 19: 2031-2040. https://doi.org/10.1097/MIB.0b013e3182920108; PMid:23811638

22. Fernandez I, Patey N, Marchand V et al. (2014). Multiple intestinal atresia with combined immune deficiency related to TTC7A defect is a multiorgan pathology: study of a French-Canadian-based cohort. Medicine (Baltimore). 93: e327. https://doi.org/10.1097/MD.0000000000000327; PMid:25546680 PMCid:PMC4602622

23. Ferry GD, Kirschner BS, Grand RJ et al. (1993). Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr. 17: 32-38. https://doi.org/10.1097/00005176-199307000-00005; PMid:8102399

24. Fuentes D, Torrente F, Keady S et al. (2003). High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther. 17: 913-921. https://doi.org/10.1046/j.1365-2036.2003.01540.x; PMid:12656694

25. Glocker EO, Frede N, Perro M et al. (2010). Infant colitis – it's in the genes. Lancet. 376: 1272. https://doi.org/10.1016/S0140-6736(10)61008-2

26. Glocker EO, Kotlarz D, Boztug K et al. (2009). Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 361: 2033-2045. https://doi.org/10.1056/NEJMoa0907206; PMid:19890111 PMCid:PMC2787406

27. Green TJ, Issenman RM, Jacobson K. (1998). Patients' diets and preferences in a pediatric population with inflammatory bowel disease. Can J Gastroenterol. 12: 544-549. https://doi.org/10.1155/1998/928706; PMid:9926264

28. Hanai HIT, Takeuchi K et al. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 4: 1502-1506. https://doi.org/10.1016/j.cgh.2006.08.008; PMid:17101300

29. Hata K, Watanabe T, Shinozaki M et al. (2003). Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 38: 1055-1058. https://doi.org/10.1080/00365520310005938; PMid:14621280

30. Henker J, Muller S, Laass MW et al. (2008). Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol. 46: 874-875. https://doi.org/10.1055/s-2008-1027463; PMid:18810672

31. Heyman MB, Kierkus J, Spenard J et al. (2010). Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 16: 1931-1939. https://doi.org/10.1002/ibd.21256; PMid:20848454 PMCid:PMC3252049

32. Huynh HQ, deBruyn J, Guan L et al. (2009). Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 15: 760-768. https://doi.org/10.1002/ibd.20816; PMid:19067432

33. Hyams J, Markowitz J, Lerer T et al. (2006). The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 4: 1118-1123. https://doi.org/10.1016/j.cgh.2006.04.008; PMid:16820327

34. Ikeda H, Ishimaru Y, Takayasu H et al. (2006). Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr. 43: 592-596. https://doi.org/10.1097/01.mpg.0000237928.07729.79; PMid:17130733

35. Jacobstein DA, Markowitz JE, Kirschner BS et al. (2005). Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 11: 442-446. https://doi.org/10.1097/01.MIB.0000158166.88238.ea; PMid:15867583

36. Jose FA, Garnett EA, Vittinghoff E et al. (2009). Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 15: 63-68. https://doi.org/10.1002/ibd.20604; PMid:18626963 PMCid:PMC2605161

37. Kader HA, Mascarenhas MR, Piccoli DA et al. (1999). Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 28: 54-58. https://doi.org/10.1097/00005176-199901000-00013; PMid:9890469

38. Kammermeier J, Dziubak R, Pescarin M et al. (2017). Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years. J Crohns Colitis. 11: 60-69. https://doi.org/10.1093/ecco-jcc/jjw118; PMid:27302973 PMCid:PMC5885808

39. Kellermayer R, Nagy Szakal D, Harris RA et al. (2015). Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. Am J Gastroenterol. 110: 604-606. https://doi.org/10.1038/ajg.2015.19; PMid:25853207 PMCid:PMC4883582

40. Kennedy NA, Rhatigan E, Arnott ID et al. (2013). A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 38: 1255-1266. https://doi.org/10.1111/apt.12511; PMid:24117596

41. Khan KJ, Ullman TA, Ford AC et al. (2011). Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 661-673. https://doi.org/10.1038/ajg.2011.72; PMid:21407187

42. Kirschner BS. (1998). Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 115: 813-821. https://doi.org/10.1016/S0016-5085(98)70251-3

43. Knod JL, Holder M, Cortez AR et al. (2016). Surgical outcomes, bowel habits and quality of life in young patients after ileoanal anastomosis for ulcerative colitis. J Pediatr Surg. 51: 1246-1250. https://doi.org/10.1016/j.jpedsurg.2016.03.002; PMid:27417342

44. Koivusalo A, Pakarinen MP, Rintala RJ. (2007). Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Surg. 42: 290-295. https://doi.org/10.1016/j.jpedsurg.2006.10.001; PMid:17270537

45. Koletzko S, Niggemann B, Arato A et al. (2012). Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroenterol Nutr. 55: 221-229. https://doi.org/10.1097/MPG.0b013e31825c9482; PMid:22569527

46. Kruis W, Fric P, Pokrotnieks J et al. (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 53: 1617-1623. https://doi.org/10.1136/gut.2003.037747; PMid:15479682 PMCid:PMC1774300

47. Kruis W, Schutz E, Fric P et al. (1997). Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 11: 853-858. https://doi.org/10.1046/j.1365-2036.1997.00225.x; PMid:9354192

48. Kunde S, Pham A, Bonczyk S et al. (2013). Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 56: 597-601. https://doi.org/10.1097/MPG.0b013e318292fa0d; PMid:23542823

49. Lahdenne P, Wikstrom AM, Aalto K et al. (2010). Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken). 62: 785-790. https://doi.org/10.1002/acr.20246; PMid:20535789

50. Lamet M. (2011). A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 56: 513-522. https://doi.org/10.1007/s10620-010-1334-y; PMid:20676771 PMCid:PMC3029674

51. Lang A, Salomon N, Wu JC et al. (2015). Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 13: 1444-1449. https://doi.org/10.1016/j.cgh.2015.02.019; PMid:25724700

52. Langhorst J, Wulfert H, Lauche R et al. (2015). Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohn Colitis. 9: 86-106. https://doi.org/10.1093/ecco-jcc/jju007; PMid:25518050

53. Langmead L, Feakins RM, Goldthorpe S et al. (2004). Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 19: 739-747. https://doi.org/10.1111/j.1365-2036.2004.01902.x; PMid:15043514

54. Lawrance IC, Baird A, Lightower D et al. (2017). Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis. Clin Gastroenterol Hepatol. 15: 1248-1255. https://doi.org/10.1016/j.cgh.2017.02.027; PMid:28286194

55. Lawrance IC, Copeland TS. (2008). Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 28: 1214-1220. https://doi.org/10.1111/j.1365-2036.2008.03841.x; PMid:18761706

56. Lee CH, Tasker N, La Hei E et al. (2014). Raised tacrolimus level and acute renal injury associated with acute gastroenteritis in a child receiving local rectal tacrolimus. Clin J Gastroenterol. 7: 238-242. https://doi.org/10.1007/s12328-014-0482-6; PMid:26183743

57. Lemoine R, Pachlopnik Schmid J, Farin HF et al. (2014). Immune deficiency-related enteropathy-lymphocytopenia-alopecia syndrome results from tetratricopeptide repeat domain 7A deficiency. J Allergy Clin Immunol. 134: 1354-1364. https://doi.org/10.1016/j.jaci.2014.07.019; PMid:25174867

58. Lewis JD, Abreu MT. (2017). Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology. 152: 398-414. https://doi.org/10.1053/j.gastro.2016.10.019; PMid:27793606

59. Lipman JM, Kiran RP, Shen B et al. (2011). Perioperative factors during ileal pouch-anal anastomosis predict pouchitis. Dis Colon Rectum. 54: 311-317. https://doi.org/10.1007/DCR.0b013e3181fded4d; PMid:21304302

60. Marshall JK, Thabane M, Steinhart AH et al. (2010). Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 1: CD004115. https://doi.org/10.1002/14651858.CD004115.pub2; PMid:20091560

61. Marshall JK, Thabane M, Steinhart AH et al. (2012). Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 11: CD004118. https://doi.org/10.1002/14651858.CD004118.pub2; PMid:23152224

62. Marteau P, Probert CS, Lindgren S et al. (2005). Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 54: 960-965. https://doi.org/10.1136/gut.2004.060103; PMid:15951542 PMCid:PMC1774619

63. Martin de Carpi J, Vilar P, Prieto G et al. (2008). Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr. 46: 386-391. https://doi.org/10.1097/MPG.0b013e31815604e5; PMid:18367949

64. Meier CB, Hegazi RA, Aisenberg J et al. (2005). Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis. 11: 965-971. https://doi.org/10.1097/01.MIB.0000186407.25694.cf; PMid:16239841

65. Merkley SA, Beaulieu DB, Horst S et al. (2015). Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments. Inflamm Bowel Dis. 21: 1854-1859. https://doi.org/10.1097/MIB.0000000000000456; PMid:25993689

66. Merrett MN, Mortensen N, Kettlewell M et al. (1996). Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut. 38: 362-364. https://doi.org/10.1136/gut.38.3.362; PMid:8675087 PMCid:PMC1383063

67. Miele E, Shamir R, Aloi M et al. (2018). Nutrition in paediatric inflammatory bowel disease: a position paper on behalf of The Porto IBD Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 66: 687-708. https://doi.org/10.1097/MPG.0000000000001896; PMid:29570147

68. Moes N, Rieux Laucat F, Begue B et al. (2010). Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology. 139: 770-778. https://doi.org/10.1053/j.gastro.2010.06.006; PMid:20537998

69. Naidoo K, Gordon M, Fagbemi AO et al. (2011). Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 12: CD007443. https://doi.org/10.1002/14651858.CD007443.pub2; PMid:22161412

70. Nanau RM, Cohen LE, Neuman MG. (2014). Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci. 17: 485-531. https://doi.org/10.18433/J3GG6D; PMid:25579431

71. Ng SC, Lam YT, Tsoi KK et al. (2013). Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 38: 854-863. https://doi.org/10.1111/apt.12464; PMid:23981095

72. Nikfar S, Rahimi R, Rezaie A et al. (2009). A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 54: 1157-1170. https://doi.org/10.1007/s10620-008-0481-x; PMid:18770034

73. Охотнікова ОМ, Ткачова ТМ, Романчук АА, Грищенко ОМ, Вороняк ДІ. (2019). Сучасний алгоритм діагностики виразкового коліту у дітей відповідно до останніх рекомендацій Європейської організації з вивчення хвороби Крона і коліту та Європейського товариства дитячих гастроентерологів, гепатологів та. Сучасна педіатрія. Україна. 7(103): 33-43. https://doi.org/10.15574/SP.2019.103.33.

74. Oliva Hemker M, Hutfless S, Al Kazzi ES et al. (2015). Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large North American cohort. J Pediatr. 167: 527-532. https://doi.org/10.1016/j.jpeds.2015.04.045; PMid:25982142

75. Orlanski Meyer E, Topf Olivestone C, Ledder O et al. (2017). Pouchitis in paediatric UC: a multicentre longitudinal cohort study from the Porto IBD working group of ESPGHAN. ESPGHAN Annual Meeting, Prague; Abstr G-O-038. https://doi.org/10.1093/ecco-jcc/jjx002.284

76. Ozdemir Y, Kiran RP, Erem HH et al. (2014). Functional outcomes and complications after restorative proctocolectomy and ileal pouch anal anastomosis in the pediatric population. J Am Coll Surg. 218: 328-335. https://doi.org/10.1016/j.jamcollsurg.2013.11.019; PMid:24468224

77. Pachlopnik Schmid J, Canioni D, Moshous D et al. (2011). Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 117: 1522-1529. https://doi.org/10.1182/blood-2010-07-298372; PMid:21119115

78. Pakarinen MP, Natunen J, Ashorn M et al. (2009). Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics. 123: 1377-1382. https://doi.org/10.1542/peds.2008-2086; PMid:19403505

79. Patton D, Gupta N, Wojcicki JM et al. (2010). Postoperative outcome of colectomy for pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 51: 151-154. https://doi.org/10.1097/MPG.0b013e3181c99290; PMid:20410838 PMCid:PMC3119923

80. Polites SF, Potter DD, Moir CR et al. (2015). Long-term outcomes of ileal pouch-anal anastomosis for pediatric chronic ulcerative colitis. J Pediatr Surg. 50: 1625-1629. https://doi.org/10.1016/j.jpedsurg.2015.03.044; PMid:25863545

81. Pozler O, Chladek J, Maly J et al. (2010). Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J Crohns Colitis. 4: 623-628. https://doi.org/10.1016/j.crohns.2010.06.005; PMid:21122571

82. Prenzel F, Uhlig HH. (2009). Frequency of indeterminate colitis in children and adults with IBD-a metaanalysis. J Crohns Colitis. 3: 277-281. https://doi.org/10.1016/j.crohns.2009.07.001; PMid:21172287

83. Probert CS, Dignass AU, Lindgren S et al. (2014). Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 8: 200-207. https://doi.org/10.1016/j.crohns.2013.08.007; PMid:24012063

84. Rembacken BJ, Snelling AM, Hawkey PM et al. (1999). Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 354: 635-639. https://doi.org/10.1016/S0140-6736(98)06343-0

85. Ruuska T, Wewer V, Lindgren F et al. (2009). Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives. Inflamm Bowel Dis. 15: 1049-1054. https://doi.org/10.1002/ibd.20859; PMid:19137602

86. Sandborn WJ, Landers CJ, Tremaine WJ et al. (1995). Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouchanal anastomosis. Am J Gastroenterol. 90: 740-747.

87. Sandborn WJ. (1996). A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 91: 423-433.

88. Seetharamaiah R, West BT, Ignash SJ et al. (2009). Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analysis. J Pediatr Surg. 44: 1410-1417. https://doi.org/10.1016/j.jpedsurg.2009.01.006; PMid:19573671

89. Shannon A, Eng K, Kay M et al. (2016). Long-term follow up of ileal pouch anal anastomosis in a large cohort of pediatric and young adult patients with ulcerative colitis. J Pediatr Surg. 51: 1181-1186. https://doi.org/10.1016/j.jpedsurg.2015.12.012; PMid:26876089

90. Suskind DL, Singh N, Nielson H et al. (2015). Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 60: 27-29. https://doi.org/10.1097/MPG.0000000000000544; PMid:25162366

91. Suskind DL, Wahbeh G, Burpee T et al. (2013). Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 56: 277-279. https://doi.org/10.1097/MPG.0b013e318276977d; PMid:23059643 PMCid:PMC3701433

92. Tajiri H, Tomomasa T, Yoden A et al. (2008). Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion. 77: 150-154. https://doi.org/10.1159/000140974; PMid:18577852

93. Tanaka T, Okanobu H, Kuga Y et al. (2010). Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 34: 687-695. https://doi.org/10.1016/j.gcb.2010.08.007; PMid:20934287

94. Tomomasa T, Kobayashi A, Kaneko H et al. (2003). Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 48: 750-754.

95. Tomomasa T, Tajiri H, Kagimoto S et al. (2011). Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 53: 34-39. https://doi.org/10.1097/MPG.0b013e31821058bc; PMid:21694533

96. Torgerson TR, Linane A, Moes N et al. (2007). Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology. 132: 1705-1717. https://doi.org/10.1053/j.gastro.2007.02.044; PMid:17484868

97. Tung J, Loftus EV Jr, Freese DK et al. (2006). A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 12: 1093-1100. https://doi.org/10.1097/01.mib.0000235835.32176.85; PMid:17119382

98. Turner D, Yerushalmi B, Kori M et al. (2017). Once-versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: a randomised controlled trial. J Crohns Colitis. 11: 527-533. https://doi.org/10.1093/ecco-jcc/jjw180; PMid:28453754

99. Tyler AD, Milgrom R, Xu W et al. (2012). Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 10: 507-512. https://doi.org/10.1016/j.cgh.2011.09.016; PMid:21963956

100.Uhlig HH, Schwerd T, Koletzko S et al. (2014). The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 147: 990-1007. https://doi.org/10.1053/j.gastro.2014.07.023; PMid:25058236 PMCid:PMC5376484

101.Van Limbergen J, Russell RK, Drummond HE et al. (2008). Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 135: 1114-1122. https://doi.org/10.1053/j.gastro.2008.06.081; PMid:18725221

102.Verhave M, Winter HS, Grand RJ. (1990). Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 117: 809-814. https://doi.org/10.1016/S0022-3476(05)83349-9

103.Wang SL, Wang ZR, Yang CQ. (2012). Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 4: 1051-1056. https://doi.org/10.3892/etm.2012.718; PMid:23226773 PMCid:PMC3494118

104.Watanabe M, Nishino H, Sameshima Y et al. (2013). Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo-controlled study. Aliment Pharmacol Ther. 38: 264-273. https://doi.org/10.1111/apt.12362; PMid:23734840

105.Wildin RS, Ramsdell F, Peake J et al. (2001). X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 27: 18-20. https://doi.org/10.1038/83707; PMid:11137992

106.Winter HS, Krzeski P, Heyman MB et al. (2014). High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. J Pediatr Gastroenterol Nutr. 59: 767-772. https://doi.org/10.1097/MPG.0000000000000530; PMid:25419597 PMCid:PMC4255757

107.Wu XR, Ashburn J, Remzi FH et al. (2016). Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg. 20: 631-639. https://doi.org/10.1007/s11605-015-2976-z; PMid:26446071